Successful Portfolios LLC bought a new position in Bristol-Myers Squibb Co (NYSE:BMY) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 4,362 shares of the biopharmaceutical company’s stock, valued at approximately $221,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Private Ocean LLC bought a new stake in shares of Bristol-Myers Squibb in the 1st quarter worth about $28,000. Lenox Wealth Advisors LLC increased its stake in Bristol-Myers Squibb by 555.7% in the 3rd quarter. Lenox Wealth Advisors LLC now owns 636 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 539 shares during the period. Endurance Wealth Management Inc. increased its stake in Bristol-Myers Squibb by 119.6% in the 2nd quarter. Endurance Wealth Management Inc. now owns 918 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 500 shares during the period. HMS Capital Management LLC purchased a new position in Bristol-Myers Squibb in the 2nd quarter worth about $45,000. Finally, Global Trust Asset Management LLC increased its stake in Bristol-Myers Squibb by 251.1% in the 2nd quarter. Global Trust Asset Management LLC now owns 3,511 shares of the biopharmaceutical company’s stock worth $48,000 after buying an additional 2,511 shares during the period. Hedge funds and other institutional investors own 80.17% of the company’s stock.
NYSE BMY traded up $0.83 during trading on Friday, reaching $51.61. 11,252,303 shares of the company’s stock traded hands, compared to its average volume of 9,791,409. The company has a debt-to-equity ratio of 1.51, a current ratio of 3.88 and a quick ratio of 3.75. The firm has a market cap of $82.38 billion, a price-to-earnings ratio of 12.97, a price-to-earnings-growth ratio of 2.48 and a beta of 0.72. The company’s 50 day simple moving average is $49.24 and its two-hundred day simple moving average is $47.03. Bristol-Myers Squibb Co has a 12-month low of $42.48 and a 12-month high of $60.77.
The firm also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be given a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a yield of 3.18%. The ex-dividend date of this dividend is Thursday, October 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 41.21%.
BMY has been the topic of several recent analyst reports. Atlantic Securities raised shares of Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 price target on the stock in a research note on Wednesday, August 14th. Bank of America raised their price target on shares of Bristol-Myers Squibb from $49.00 to $50.00 and gave the stock a “neutral” rating in a research note on Thursday. UBS Group reduced their price target on shares of Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating on the stock in a research note on Thursday, June 13th. TheStreet raised shares of Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a research note on Wednesday, September 18th. Finally, JPMorgan Chase & Co. set a $62.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Friday, September 13th. Eight investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Bristol-Myers Squibb currently has an average rating of “Buy” and an average price target of $55.81.
In other Bristol-Myers Squibb news, Director Robert J. Bertolini bought 11,000 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were acquired at an average price of $44.72 per share, with a total value of $491,920.00. Following the transaction, the director now owns 11,397 shares of the company’s stock, valued at approximately $509,673.84. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.13% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
See Also: P/E Growth (PEG)
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.